NVCT
Nuvectis Pharma Inc
20.20$
-6.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 100.0% | – | – | – | 100.0% | 100.0% | – | – | – | – | – | – | 100.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | 50.0% | – | – | – | – | – | – | – | |
| – | – | – | 100.0% | – | – | – | 100.0% | 100.0% | – | – | – | – | – | – | 50.0% | – | – | – | – | – | – | – | |
| – | – | – | 28,600.0% | – | – | – | 2,951.0% | 57.7% | – | – | – | – | – | – | 16.8% | – | – | – | – | – | – | – | |
| – | – | – | 28,025.0% | – | – | – | 1,598.0% | 42.3% | – | – | – | – | – | – | 7.3% | – | – | – | – | – | – | – | |
| – | – | – | 56,625.0% | – | – | – | 4,549.0% | 100.0% | – | – | – | – | – | – | 24.1% | – | – | – | – | – | – | – | |
| – | – | – | -56,625.0% | – | – | – | -4,549.0% | -100.0% | – | – | – | – | – | – | -24.1% | – | – | – | – | – | – | – | |
| – | – | – | 100.0% | – | – | – | 55.0% | 1.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -56,525.0% | – | – | – | -4,494.0% | -98.7% | – | – | – | – | – | – | -23.3% | – | – | – | – | – | – | – | |
| – | – | – | -100.0% | – | – | – | -110.1% | -1.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -56,525.0% | – | – | – | -4,494.0% | -98.7% | – | – | – | – | – | – | -23.3% | – | – | – | – | – | – | – | |
| – | – | – | -56,525.0% | – | – | – | -4,494.0% | -98.7% | – | – | – | – | – | – | -23.3% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.